Literature DB >> 9486202

Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener.

I S Farrukh1, W Peng, U Orlinska, J R Hoidal.   

Abstract

In the present study, we investigated the effects of the naturally occurring hormone dehydroepiandrosterone (DHEA) on hypoxic pulmonary vasoconstriction (HPVC) in isolated ferret lungs and on K+ currents in isolated and cultured ferret pulmonary arterial smooth muscle cells (FPSMCs). Severe alveolar hypoxia (3% O2-5% CO2-92% N2) caused an initial increase in pulmonary arterial pressure (Ppa) that was followed by a reversal in pulmonary hypertension. Maintaining alveolar hypoxia caused a sustained secondary increase in Ppa. Pretreating the lungs with the K(+)-channel inhibitor tetraethylammonium (TEA) caused a small increase in baseline Ppa, potentiated HPVC, and prevented the reversal of HPVC during the sustained alveolar hypoxia. Treating the lungs with DHEA caused a near-complete reversal of HPVC in control lungs and in lungs that were pretreated with TEA. DHEA also reversed the KCl-induced increase in Ppa. In FPSMCs, DHEA caused an adenosine 3',5'-cyclic monophosphate- and guanosine 3',5'-cyclic monophosphate-independent increase in activity of the Ca(2+)-activated K+ (KCa) current. In a cell-attached configuration, DHEA caused a mean shift of -22 mV in the voltage-dependent activation of the KCa channel. We conclude that DHEA is a novel KCa-channel opener of the pulmonary vasculature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486202     DOI: 10.1152/ajplung.1998.274.2.L186

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  19 in total

Review 1.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 2.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

3.  Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels.

Authors:  Amy L Firth; Carmelle V Remillard; Oleksandr Platoshyn; Ivana Fantozzi; Eun A Ko; Jason X-J Yuan
Journal:  Pulm Circ       Date:  2011-01-01       Impact factor: 3.017

Review 4.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

Review 5.  Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Womens Health (Lond)       Date:  2010-03

Review 6.  Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.

Authors:  Sylvie Legrain; Laurence Girard
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  Oxidant and redox signaling in vascular oxygen sensing: implications for systemic and pulmonary hypertension.

Authors:  Sachin A Gupte; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2008-06       Impact factor: 8.401

8.  Dehydroepiandrosterone inhibits ICa,L and its window current in voltage-dependent and -independent mechanisms in arterial smooth muscle cells.

Authors:  Rikuo Ochi; Sukrutha Chettimada; Igor Kizub; Sachin A Gupte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-10-31       Impact factor: 4.733

9.  Dehydroepiandrosterone promotes pulmonary artery relaxation by NADPH oxidation-elicited subunit dimerization of protein kinase G 1α.

Authors:  Dhara Patel; Sharath Kandhi; Melissa Kelly; Boon Hwa Neo; Michael S Wolin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-27       Impact factor: 5.464

10.  Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.

Authors:  Masahiko Oka; Vijaya Karoor; Noriyuki Homma; Tetsutaro Nagaoka; Eiko Sakao; Scott M Golembeski; Jennifer Limbird; Masatoshi Imamura; Sarah A Gebb; Karen A Fagan; Ivan F McMurtry
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.